An evidence-based approach to the use of predictive biomarkers in the treatment of non- small cell lung cancer (NSCLC)

Cancers

Volumn 3, Issue 3, 2011, Pages 3506-3524

  Quinton, Cindy ^a   Ellis, Peter M ^a,b  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Biomarker; Epidermal growth factor receptor; Molecular marker; Non small cell lung cancer; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

BETA TUBULIN; BETA TUBULIN III; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FIGITUMUMAB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PLACEBO; RIBONUCLEOTIDE REDUCTASE; TAXANE DERIVATIVE; TUMOR MARKER; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN;

ADVANCED CANCER; ANAPLASTIC LYMPHOMA KINASE GENE; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EVIDENCE BASED PRACTICE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE TRANSLOCATION; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; ONCOGENE; ONCOGENE K RAS; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; RECEPTOR GENE; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 80053192292     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3033506     Document Type: Review

References (82)

1. Hansen, H.H.; Selawry, O.S.; Simon, R.; Carr, D.T.; van Wyk, C.E.; Tucker, R.D.; Sealy, R. Combination chemotherapy of advanced lung cancer: A randomized trial. Cancer 1976, 38, 2201-2207.
2. Pao, W.; Chmielecki, J. Rational, biologically based treatment of egfr-mutant non-small-cell lung cancer. Nat. Rev. Cancer 2010, 10, 760-774.
3. Anonymous chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small cell lung cancer collaborative group. Br. Med. J. 1995, 311, 899-909.
4. Scagliotti, G.V.; Parikh, P.; von Pawel, J.; Biesma, B.; Vansteenkiste, J.; Manegold, C.; Serwatowski, P.; Gatzemeier, U.; Digumarti, R.; Zukin, M. et al. Phase iii study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 2008, 26, 3543-3551.
5. Fossella, F.V.; DeVore, R.; Kerr, R.N.; Crawford, J.; Natale, R.R.; Dunphy, F.; Kalman, L.; Miller, V.; Lee, J.S.; Moore, M.; et al. Randomized phase iii trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The tax 320 non-small cell lung cancer study group. J. Clin. Oncol. 2000, 18, 2354-2362.
6. Shepherd, F.A.; Dancey, J.; Ramlau, R.; Mattson, K.; Gralla, R.; O'Rourke, M.; Levitan, N.; Gressot, L.; Vincent, M.; Burkes, R.; et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 2000, 18, 2095-2103.
7. Shepherd, F.A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E.H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005, 353, 123-132.
8. Mok, T.S.; Wu, Y.L.; Thongprasert, S.; Yang, C.H.; Chu, D.T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y.; et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361, 947-957.
9. Dancey, J.E.; Dobbin, K.K.; Groshen, S.; Jessup, J.M.; Hruszkewycz, A.H.; Koehler, M.; Parchment, R.; Ratain, M.J.; Shankar, L.K.; Stadler, W.M.; et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin. Cancer Res. 2010, 16, 1745-1755.
10. Park, S.Y.; Hong, Y.C.; Kim, J.H.; Kwak, S.M.; Cho, J.H.; Lee, H.L.; Ryu, J.S. Effect of ercc1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med. Oncol. 2006, 23, 489-498.
11. Thatcher, N.; Chang, A.; Parikh, P.; Rodrigues Pereira, J.; Ciuleanu, T.; von Pawel, J.; Thongprasert, S.; Tan, E.H.; Pemberton, K.; Archer, V.; et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (iressa survival evaluation in lung cancer). Lancet 2005, 366, 1527-1537.
12. Ciuleanu, T.; Brodowicz, T.; Zielinski, C.; Kim, J.H.; Krzakowski, M.; Laack, E.; Wu, Y.L.; Bover, I.; Begbie, S.; Tzekova, V.; et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 2009, 374, 1432-1440.
13. Sandler, A.; Gray, R.; Perry, M.C.; Brahmer, J.; Schiller, J.H.; Dowlati, A.; Lilenbaum, R.; Johnson, D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355, 2542-2550.
14. Zhu, C.Q.; Ding, K.; Strumpf, D.; Weir, B.A.; Meyerson, M.; Pennell, N.; Thomas, R.K.; Naoki, K.; Ladd-Acosta, C.; Liu, N.; et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J. Clin. Oncol. 2010, 28, 4417-4424.
15. Saloura, V.; Wang, L.; Schwed, D.; Vachani, A.; Langer, C.J.; Albelda, S. Personalizing treatment with pemetrexed (pem) in patients with malignant mesothelioma (mpm) and non-small cell lung cancer (nsclc): The role of thimidylate synthase. ASCO Meet. Abstr. 2010, 28, e21001.
16. Hanna, N.; Shepherd, F.A.; Fossella, F.V.; Pereira, J.R.; de Marinis, F.; von Pawel, J.; Gatzemeier, U.; Tsao, T.C.; Pless, M.; Muller, T.; et al. Randomized phase iii trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004, 22, 1589-1597.
17. Peterson, P.; Park, K.; Fossella, F.; Gatzemeier, U.; John, W.; Scagliotti, G.V. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase iii trial of pemetrexed vs. docetaxel in previously treated patients with advanced non-small cell lung cancer (nsclc). J. Thorac. Oncol. 2007, 2, PS851.
18. Ceppi, P.; Volante, M.; Saviozzi, S.; Rapa, I.; Novello, S.; Cambieri, A.; Lo Iacono, M.; Cappia, S.; Papotti, M.; Scagliotti, G.V. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger rna and protein levels for thymidylate synthase. Cancer 2006, 107, 1589-1596.
19. Scagliotti, G.; Hanna, N.; Fossella, F.; Sugarman, K.; Blatter, J.; Peterson, P.; Simms, L.; Shepherd, F.A. The differential efficacy of pemetrexed according to nsclc histology: A review of two phase iii studies. Oncologist 2009, 14, 253-263.
20. Grønberg, B.H.; Bremnes, R.M.; Fløtten, Ø.; Amundsen, T.; Brunsvig, P.F.; Hjelde, H.H.; Kaasa, S.; von Plessen, C.; Stornes, F.; Tollåli, T.; et al. Phase iii study by the norwegian lung cancer study group: Pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 2009, 27, 3217-3224.
21. Chansky, K.; Mack, P.C.; Crowley, J.J.; Lara, P.N.; Hirsch, F.R.; Franklin, W.A.; Gandara, D.R. Chemotherapy outcomes by histologic subtype of non-small cell lung cancer (NSCLC): Analysis of the swog database for antimicrotubule-platinum therapy. J. Thorac. Oncol. 2009, 4, abstract B2.7.
22. O'Byrne, K.J.; Bondarenko, I.; Barrios, C.; Eschbach, C.; Martens, U.; Hotko, Y.; Kortsik, C.; Celik, I.; Stroh, C.; Pirker, R. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (nsclc): Data from the flex study. J. Clin. Oncol. 2009, 27, abstract 8007.
23. Pirker, R.; Pereira, J.R.; Szczesna, A.; von Pawel, J.; Krzakowski, M.; Ramlau, R.; Vynnychenko, I.; Park, K.; Yu, C.T.; Ganul, V.; et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (flex): An open-label randomised phase iii trial. Lancet 2009, 373, 1525-1531.
24. Johnson, D.H.; Fehrenbacher, L.; Novotny, W.F.; Herbst, R.S.; Nemunaitis, J.J.; Jablons, D.M.; Langer, C.J.; DeVore, R.F., 3rd; Gaudreault, J.; Damico, L.A.; et al. Randomized phase ii trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 2004, 22, 2184-2191.
25. Natale, R.B.; Bodkin, D.; Govindan, R.; Sleckman, B.G.; Rizvi, N.A.; Capo, A.; Germonpre, P.; Eberhardt, W.E.; Stockman, P.K.; Kennedy, S.J.; et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results from a two-part, double-blind, randomized phase ii study. J. Clin. Oncol. 2009, 27, 2523-2529.
26. Scagliotti, G.; Novello, S.; von Pawel, J.; Reck, M.; Pereira, J.R.; Thomas, M.; Abrao Miziara, J.E.; Balint, B.; De Marinis, F.; Keller, A.; et al. Phase iii study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28, 1835-1842.
27. Govindan, R. Interesting biomarker to select ideal patients for epidermal growth factor receptor tyrosine kinase inhibitors: Yes, for egfr mutation analysis, others, i pass. J. Clin. Oncol. 2010, 28, 713-715.
28. Douillard, J.-Y.; Kim, E.; Hirsh, V.; Mok, T.; Socinski, M.; Gervais, R.; Wu, Y.; Li, L.; Sellers, M.; Lowe, E. Gefitinib (iressa) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: A randomized, open-label phase iii study (interest). J. Thorac. Oncol. 2007, 2, S305-S306.
29. Khambata-Ford, S.; Harbison, C.T.; Hart, L.L.; Awad, M.; Xu, L.A.; Horak, C.E.; Dakhil, S.; Hermann, R.C.; Lynch, T.J.; Weber, M.R. Analysis of potential predictive markers of cetuximab benefit in bms099, a phase iii study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28, 918-927.
30. Cappuzzo, F.; Ciuleanu, T.; Stelmakh, L.; Cicenas, S.; Szczesna, A.; Juhasz, E.; Esteban, E.; Molinier, O.; Brugger, W.; Melezinek, I.; et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010, 11, 521-529.
31. Herbst, R.S.; Prager, D.; Hermann, R.; Fehrenbacher, L.; Johnson, B.E.; Sandler, A.; Kris, M.G.; Tran, H.T.; Klein, P.; Li, X.; et al. Tribute: A phase iii trial of erlotinib hydrochloride (osi-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 2005, 23, 5892-5899.
32. Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; de Rosa, F.; Milanowski, J.; Karnicka-Mlodkowski, H.; Pesek, M.; Serwatowski, P.; et al. Phase iii study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The tarceva lung cancer investigation trial. J. Clin. Oncol. 2007, 25, 1545-1552.
33. Bell, D.W.; Lynch, T.J.; Haserlat, S.M.; Harris, P.L.; Okimoto, R.A.; Brannigan, B.W.; Sgroi, D.C.; Muir, B.; Riemenschneider, M.J.; Iacona, R.B.; et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the ideal/intact gefitinib trials. J. Clin. Oncol. 2005, 23, 8081-8092.
34. Giaccone, G.; Herbst, R.S.; Manegold, C.; Scagliotti, G.; Rosell, R.; Miller, V.; Natale, B.; Schiller, J.H.; von Pawel, J.; Pluzanska, A.; et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase iii trial-Intact 1. J. Clin. Oncol. 2004, 22, 777-784.
35. Herbst, R.S.; Giaccone, G.; Schiller, J.H.; Natale, R.B.; Miller, V.; Manegold, C.; Scagliotti, G.; Rosell, R.; Oliff, I.; Reeves, J.A.; et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase iii trial-Intact 2. J. Clin. Oncol. 2004, 22, 785-794.
36. Douillard, J.Y.; Shepherd, F.A.; Hirsh, V.; Mok, T.; Socinski, M.A.; Gervais, R.; Liao, M.L.; Bischoff, H.; Reck, M.; Sellers, M.V.; et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase iii interest trial. J. Clin. Oncol. 2010, 28, 744-752.
37. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
38. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; et al. Egfr mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
39. Pao, W.; Miller, V.; Zakowski, M.; Doherty, J.; Politi, K.; Sarkaria, I.; Singh, B.; Heelan, R.; Rusch, V.; Fulton, L.; et al. Egf receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 2004, 101, 13306-13311.
40. Coate, L.E.; John, T.; Tsao, M.S.; Shepherd, F.A. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol. 2009, 10, 1001-1010.
41. Dahabreh, I.J.; Linardou, H.; Siannis, F.; Kosmidis, P.; Bafaloukos, D.; Murray, S. Somatic egfr mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 2010, 16, 291-303.
42. Lee, J.S.; Park, K.; Kim, S.W.; Lee, D.H.; Kim, H.T.; Han, J.Y.; Yun, T.; Ahn, M.J.; Ahn, J.S.; Suh, C.; et al. A randomized phase iii study of gefitinib (iressatm) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J. Thorac. Oncol. 2009, 4, S283-S284.
43. Takeda, K.; Hida, T.; Sato, T.; Ando, M.; Seto, T.; Satouchi, M.; Ichinose, Y.; Katakami, N.; Yamamoto, N.; Kudoh, S.; et al. Randomized phase iii trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: Results of a west japan thoracic oncology group trial (wjtog0203). J. Clin. Oncol. 2010, 28, 753-760.
44. Ogita, S.; Wozniak, A.J. Refining the treatment of advanced nonsmall cell lung cancer. Lung Cancer 2010, 1, 9-22.
45. Van Cutsem, E.; Kohne, C.H.; Hitre, E.; Zaluski, J.; Chang Chien, C.R.; Makhson, A.; D'Haens, G.; Pinter, T.; Lim, R.; Bodoky, G.; et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009, 360, 1408-1417.
46. Zhu, C.Q.; da Cunha Santos, G.; Ding, K.; Sakurada, A.; Cutz, J.C.; Liu, N.; Zhang, T.; Marrano, P.; Whitehead, M.; Squire, J.A.; et al. Role of kras and egfr as biomarkers of response to erlotinib in national cancer institute of canada clinical trials group study br.21. J. Clin. Oncol. 2008, 26, 4268-4275.
47. Winton, T.; Livingston, R.; Johnson, D.; Rigas, J.; Johnston, M.; Butts, C.; Cormier, Y.; Goss, G.; Inculet, R.; Vallieres, E.; et al. Vinorelbine plus cisplatin vs. Observation in resected non-small-cell lung cancer. N. Engl. J. Med. 2005, 352, 2589-2597.
48. Schiller, J.H.; Harrington, D.; Belani, C.P.; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D.H.; The Eastern Cooperative Oncology, G. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346, 92-98.
49. Olaussen, K.A.; Dunant, A.; Fouret, P.; Brambilla, E.; Andre, F.; Haddad, V.; Taranchon, E.; Filipits, M.; Pirker, R.; Popper, H.H.; et al. DNA repair by ercc1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006, 355, 983-991.
50. Toschi, L.; Cappuzzo, F. Impact of biomarkers on non-small cell lung cancer treatment. Target. Oncol. 2010, 5, 5-17.
51. Simon, G.; Sharma, A.; Li, X.; Hazelton, T.; Walsh, F.; Williams, C.; Chiappori, A.; Haura, E.; Tanvetyanon, T.; Antonia, S.; et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 2007, 25, 2741-2746.
52. Rosell, R.; Skrzypski, M.; Jassem, E.; Taron, M.; Bartolucci, R.; Sanchez, J.J.; Mendez, P.; Chaib, I.; Perez-Roca, L.; Szymanowska, A.; et al. Brca1: A novel prognostic factor in resected non-small-cell lung cancer. PLoS One 2007, 2, e1129.
53. Reynolds, C.; Obasaju, C.; Schell, M.J.; Li, X.; Zheng, Z.; Boulware, D.; Caton, J.R.; Demarco, L.C.; O'Rourke, M.A.; Shaw Wright, G.; et al. Randomized phase iii trial of gemcitabine-based chemotherapy with in situ rrm1 and ercc1 protein levels for response prediction in non-small-cell lung cancer. J. Clin. Oncol. 2009, 27, 5808-5815.
54. Rosell, R.; Taron, M.; Alberola, V.; Massuti, B.; Felip, E. Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 2003, 41, S97-S102.
55. Bepler, G.; Zheng, Z.; Gautam, A.; Sharma, S.; Cantor, A.; Sharma, A.; Cress, W.D.; Kim, Y.C.; Rosell, R.; McBride, C.; et al. Ribonucleotide reductase m1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 2005, 47, 183-192.
56. Seve, P.; Reiman, T.; Dumontet, C. The role of betaiii tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer 2010, 67, 136-143.
57. Kang, C.H.; Jang, B.G.; Kim, D.W.; Chung, D.H.; Kim, Y.T.; Jheon, S.; Sung, S.W.; Kim, J.H. The prognostic significance of ercc1, brca1, xrcc1, and betaiii-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 2010, 68, 478-483.
58. Reiman, T.; Seve, P.; Veillard, A.S.; Soria, J.C.; Rosell, R.; Taron, M.; Graziano, S.; Kratzke, R.; Seymour, L.; Shepherd, F.; et al. Validation of the prognostic and predictive value of class iii beta tubulin (tubb3) for adjuvant chemotherapy (act) in completely resected non-small cell lung cancer (r-nsclc): Results from four randomized trials. J. Thorac. Oncol. 2009, 4, Abstract S298.
59. Dowlati, A.; Gray, R.; Sandler, A.B.; Schiller, J.H.; Johnson, D.H. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-An eastern cooperative oncology group study. Clin. Cancer Res. 2008, 14, 1407-1412.
60. Leighl, N.; Reck, M.; de Haas, S.; Evers, S.; Delmar, P.; Manegold, C.; Scherer, S. Analysis of biomarkers (bms) in the avail phase iii randomised study of first-line bevacizumab (bv) with cisplatin-gemcitabine (cg) in patients (pts) with non-small cell lung cancer (NSCLC). Eur. J. Cancer Suppl. 2009, 7, 558.
61. Hanrahan, E.O.; Lin, H.Y.; Kim, E.S.; Yan, S.; Du, D.Z.; McKee, K.S.; Tran, H.T.; Lee, J.J.; Ryan, A.J.; Langmuir, P.; et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J. Clin. Oncol. 2010, 28, 193-201.
62. Herbst, R.S.; Sun, Y.; Eberhardt, W.E.; Germonpre, P.; Saijo, N.; Zhou, C.; Wang, J.; Li, L.; Kabbinavar, F.; Ichinose, Y.; et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (zodiac): A double-blind, randomised, phase 3 trial. Lancet Oncol. 2010, 11, 619-626.
63. Dahlberg, S.E.; Sandler, A.B.; Brahmer, J.R.; Schiller, J.H.; Johnson, D.H. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ecog 4599. J. Clin. Oncol. 2010, 28, 949-954.
64. Goodwin, R.; Ding, K.; Seymour, L.; LeMaître, A.; Arnold, A.; Shepherd, F.A.; Dediu, M.; Ciuleanu, T.; Fenton, D.; Zukin, M.; et al. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: Ncic clinical trials group study br24. Ann. Oncol. 2010, 21, 2220-2226.
65. Tsao, M.S.; Aviel-Ronen, S.; Ding, K.; Lau, D.; Liu, N.; Sakurada, A.; Whitehead, M.; Zhu, C.Q.; Livingston, R.; Johnson, D.H.; et al. Prognostic and predictive importance of p53 and ras for adjuvant chemotherapy in non small-cell lung cancer. J. Clin. Oncol. 2007, 25, 5240-5247.
66. Hallberg, B.; Palmer, R.H. Crizotinib-Latest champion in the cancer wars? N. Engl. J. Med. 2010, 363, 1760-1762.
67. Kwak, E.L.; Bang, Y.J.; Camidge, D.R.; Shaw, A.T.; Solomon, B.; Maki, R.G.; Ou, S.H.; Dezube, B.J.; Jänne, P.A.; Costa, D.B.; et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363, 1693-1703.
68. Addison, C.L.; Ding, K.; Zhao, H.; Le Maître, A.; Goss, G.D.; Seymour, L.; Tsao, M.-S.; Shepherd, F.A.; Bradbury, P.A. Plasma transforming growth factor ̀ and amphiregulin protein levels in ncic clinical trials group br.21. J. Clin. Oncol. 2010, 28, 5247-5256.
69. Karp, D.D.; Paz-Ares, L.G.; Novello, S.; Haluska, P.; Garland, L.; Cardenal, F.; Blakely, L.J.; Eisenberg, P.D.; Langer, C.J.; Blumenschein, G., Jr.; et al. Phase ii study of the anti-insulin-like growth factor type 1 receptor antibody cp-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J. Clin. Oncol. 2009, 27, 2516-2522.
70. Jassem, J.; Langer, C.J.; Karp, D.D.; Mok, T.; Benner, R.J.; Green, S.J.; Park, K.; Novello, S.; Strausz, J.; Gualberto, A. Randomized, open label, phase iii trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). ASCO Meet. Abstr. 2010, 28, Abstr. 7500.
71. Kasahara, K.; Arao, T.; Sakai, K.; Matsumoto, K.; Sakai, A.; Kimura, H.; Sone, T.; Horiike, A.; Nishio, M.; Ohira, T.; et al. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma. Clin. Cancer Res. 2010, 16, 4616-4624.
72. Spigel, D.R.; Ervin, T.J.; Ramlau, R.; Daniel, D.B.; Goldschmidt, J.H.; Blumenschein, G.R.; Krzakowski, M.J.; Robinet, G.; Clement-Duchene, C.; Barlesi, F.; et al. Final efficacy results from oam4558g, a randomized phase ii study evaluating metmab or placebo in combination with erlotinib in advanced NSCLC. ASCO Meet. Abstr. 2011, 29, Abstr. 7505.
73. Felip, E.; Ranson, M.; Cedres, S.; Brewster, M.; Mcnally, V.; Venturi, M.; Passioukov, A.; Ross, G.; Galdermans, D. Biomarker analyses from a phase l study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). ASCO Meet. Abstr. 2010, 28, Abstr. 7540.
74. Kumar, S.; Guleria, R.; Singh, V.; Bharti, A.C.; Mohan, A.; Das, B.C. Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer. Clin. Lung Cancer 2010, 11, 36-44.
75. Zhu, L.B.; Xu, Q.; Hong, C.Y.; Yue, Z.; Zhang, Y.; Ye, H.N.; Yuan, Y. Xpc gene intron 11 c/a polymorphism is a predictive biomarker for the sensitivity to np chemotherapy in patients with non-small cell lung cancer. Anti-Cancer Drugs 2010, 21, 669-673.
76. Chen, H.Y.; Yu, S.L.; Chen, C.H.; Chang, G.C.; Chen, C.Y.; Yuan, A.; Cheng, C.L.; Wang, C.H.; Terng, H.J.; Kao, S.F.; et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 2007, 356, 11-20.
77. Park, S.; Holmes-Tisch, A.J.; Cho, E.Y.; Shim, Y.M.; Kim, J.; Kim, H.S.; Lee, J.; Park, Y.H.; Ahn, J.S.; Park, K.; et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J. Thorac. Oncol. 2009, 4, 809-815.
78. Cortot, A.B.; Italiano, A.; Burel-Vandenbos, F.; Martel-Planche, G.; Hainaut, P. Kras mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer 2010, 116, 2682-2687.
79. Vollebergh, M.A.; Kappers, I.; Klomp, H.M.; Buning-Kager, J.C.; Korse, C.M.; Hauptmann, M.; de Visser, K.E.; van den Heuvel, M.M.; Linn, S.C. Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 2010, 5, 1939-1948.
80. Zalcman, G.; Levallet, G.; Bergot, E.; Antoine, M.; Creveuil, C.; Brambilla, E.; Dumontet, C.; Morin, F.; Depierre, A.; Milleron, B. Evaluation of class iii beta-tubulin (btubiii) expression as a prognostic marker in patients with resectable non-small cell lung cancer (nsclc) treated by perioperative chemotherapy (ct) in the phase iii trial ifct-0002. J. Clin. Oncol. 2009, 27, abstract 7526.
81. Herbst, R.S.; Blumenschein, G.R.; Kim, E.S.; Lee, J.; Tsao, A.S.; Alden, C.M.; Liu, S.; Stewart, D.J.; Wistuba, I.I.; Hong, W.K. Sorafenib treatment efficacy and kras biomarker status in the biomarker-integrated approaches of targeted therapy for lung cancer elimination (BATTLE) trial. ASCO Meet. Abstr. 2010, 28, Abstr. 7609.
82. Shepherd, F.A.; Tsao, M.S. Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: A riddle, wrapped in a mystery, inside an enigma. J. Clin. Oncol. 2010, 28, 903-905.